nach oben

Erschienen in:

01.05.2023

Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503

verfasst von: Ayako Matsuda, Kazue Yamaoka, Hideo Kunitoh, Takashi Seto, Masahiro Tsuboi, Tatsuo Ohira, Riichiroh Maruyama, Hiroaki Okamoto, Kaoru Kubota

Erschienen in: Quality of Life Research | Ausgabe 9/2023

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Purpose

The TORG0503 study was undertaken to select a preferred platinum-based third-generation regimen for patients with completely resected non-small cell lung cancer (NSCLC). This study aimed to describe the quality of life (QOL) analysis of that study.

Methods

Patients with completely resected NSCLC were randomized to receive three cycles of docetaxel plus cisplatin (DC) or paclitaxel plus carboplatin (PC) on day 1 every 3 weeks. QOL was assessed at three time points (baseline, after two cycles, and after three cycles) using the Functional Assessment of Cancer Therapy–taxane (FACT-Taxane). The adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated by logistic regression analysis that was adjusted for the baseline score in the FACT-Taxane total score and each subscale to evaluate treatment (PC vs. DC) effectiveness.

Results

QOL data from 104 patients (DC, n = 56 patients; PC, n = 48) were analyzed. In the FACT-Taxane total score, the baseline-adjusted OR (95% CI) of not worse QOL for the DC group was 3.3 (1.4–8.3) compared with the PC group. In the taxane subscale, the baseline-adjusted OR (95% CI) was 6.2 (2.6–16.0).

Conclusion

Total QOL was maintained better in the DC group than in the PC group, especially the taxane subscale that consists of neurotoxicity and taxane components in spite of no treatment-related death in both arms between DC and PC. We might recommend DC as the control regimen for the next clinical trial from the viewpoint of QOL, similar to the primary outcomes in TORG0503.

Vorheriger Artikel Characteristics of patients diagnosed with pancreatic cancer who access palliative care: An observational study

Nächster Artikel Longitudinal changes of health-related quality of life over 10 years in breast cancer patients treated with radiotherapy following breast-conserving surgery

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Nur mit Berechtigung zugänglich

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

Testa, U., Castelli, G., & Pelosi, E. (2018). Lung cancers: Molecular characterisation, clonal heterogeneity and evolution, and cancer stem cells. Cancers, 10(8), 248. https://doi.org/10.3390/cancers10080248CrossRefPubMedPubMedCentral

Jones, G. S., & Baldwin, D. R. (2018). Recent advances in the management of lung cancer. Clinical Medicine, 18(Suppl 2), s41–s46. https://doi.org/10.7861/clinmedicine.18-2-s41CrossRefPubMedPubMedCentral

Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczesna, A., Fidias, P., Millward, M., & Belani, C. P. (2003). Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. Journal of Clinical Oncology, 21(16), 3016–3024. https://doi.org/10.1200/JCO.2003.12.046CrossRefPubMed

Kubota, K., Watanabe, K., Kunitoh, H., Noda, K., Ichinose, Y., Katakami, N., Sugiura, T., Kawahara, M., Yokoyama, A., Yokota, S., Yoneda, S., Matsui, K., Kudo, S., Shibuya, M., Isobe, T., Segawa, Y., Nishiwaki, Y., Ohashi, Y., Niitani, H., et al. (2004). Phase III randomised trial of docetaxel Plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer study Group. Journal of Clinical Oncology, 22(2), 254–261. https://doi.org/10.1200/JCO.2004.06.114CrossRefPubMed

Lim, J. U., & Yeo, C. D. (2022). Update on adjuvant therapy in completely resected NSCLC patients. Thoracic Cancer, 13(3), 277–283. https://doi.org/10.1111/1759-7714.14277CrossRefPubMed

Kubota, K., Kunitoh, H., Seto, T., Shimada, N., Tsuboi, M., Ohhira, T., Okamoto, H., Masuda, N., Maruyama, R., Shibuya, M., & Watanabe, K. (2020). Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503. Lung Cancer, 141, 32–36. https://doi.org/10.1016/j.lungcan.2019.11.009CrossRefPubMed

Sugitani, Y., Sugitani, N., & Ono, S. (2020). Quantitative preferences for lung cancer treatment from the patients’ perspective: A systematic review. Patient, 13(5), 521–536. https://doi.org/10.1007/s40271-020-00434-7CrossRefPubMed

10.

Liao, K., Wang, T., Coomber-Moore, J., Wong, D. C., Gomes, F., Faivre-Finn, C., Sperrin, M., Yorke, J., & van der Veer, S. N. (2022). Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell lung cancer: A scoping review. BMC Cancer, 22(1), 1076.CrossRefPubMedPubMedCentral

11.

FACIT. org. Retrived February 18, 2022, from https://www.facit.org/measures/FACT-Taxane

12.

Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003). Measuring the side effects of taxane therapy in oncology: The functional assesment of cancer therapy-taxane (FACT-taxane). Cancer, 98(4), 822–831. https://doi.org/10.1002/cncr.11578CrossRefPubMed

13.

FACIT. org. Retrived March 1, 2022, from https://www.facit.org/measures-scoring-downloads/fact-taxane-scoring-downloads

14.

Dossing, A., Tarp, S., Furst, D. E., Gluud, C., Wells, G. A., Beyene, J., Hansen, B. B., Bliddal, H., & Christensen, R. (2016). Modified intention-to-treat analysis did not bias trial results. Journal of Clinical Epidemiology, 72, 66–74. https://doi.org/10.1016/j.jclinepi.2015.11.003CrossRefPubMed

15.

Lydersen, S. (2019). Last observation carried forward. Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin, Ny Raekke. https://doi.org/10.4045/tidsskr.19.0061CrossRefPubMed

16.

Osoba, D., Bezjak, A., Brundage, M., Zee, B., Tu, D., Pater, J., Quality of Life Committee of the NCIC CTG. (2005). Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer, 41(2), 280–287. https://doi.org/10.1016/j.ejca.2004.10.017CrossRefPubMed

17.

Carpenter, J., & Kenward, M. (2013). Multiple imputation and its application. John Wiley & Sons.CrossRef

18.

Barnes, S. A., Lindborg, S. R., & Seaman, J. W. (2006). Multiple imputation techniques in small sample clinical trials. Statistics in Medicine, 25(2), 233–245.CrossRefPubMed

19.

Kris, M. G., Gaspar, L. E., Chaft, J. E., Kennedy, E. B., Azzoli, C. G., Ellis, P. M., Lin, S. H., Pass, H. I., Seth, R., Shepherd, F. A., Spigel, D. R., Strawn, J. R., Ung, Y. C., & Weyant, M. (2017). Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-Cell lung cancers. Journal of Clinical Oncology, 35, 2960–2974. https://doi.org/10.1200/JCO.2017.72CrossRefPubMed

20.

Oizumi, S., Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Yoshizawa, H., Isobe, H., Harada, M., Kinoshita, I., Okinaga, S., Kato, T., Harada, T., Gemma, A., Saijo, Y., Yokomizo, Y., Morita, S., Hagiwara, K., & Nukiwa, T. (2012). Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of northeast Japan Study Group 002 trial. The Oncologist, 17(6), 863–870. https://doi.org/10.1634/theoncologist.2011-0426CrossRefPubMedPubMedCentral

21.

Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., Appawu, M., Iasonos, A., Atkinson, T., Goldfarb, S., Culkin, A., Kris, M. G., & Schrag, D. (2009). Adverse symptom reporting by patients versus clinicians: Relationships with clinical outcomes. Journal of the National Cancer Institute, 101(23), 1624–1632. https://doi.org/10.1093/jnci/djp386CrossRefPubMedPubMedCentral

22.

Basch, E. (2010). The missing voice of patients in drug-safety reporting. New England Journal of Medicine, 362(10), 865–869. https://doi.org/10.1056/NEJMp0911494CrossRefPubMed

23.

United States Food and Drug Administration (FDA). (2009). Guidance for industry. U.S. Department of Health and Human Services. Patient-reported outcome measures: Use in medical product development to support labeling claims. Retrived March 1, 2020, from https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf.

24.

Brundage, M., Bass, B., Davidson, J., Queenan, J., Bezjak, A., Ringash, J., Wilkinson, A., & Feldman-Stewart, D. (2011). Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Quality of Life Research, 20, 653–664.CrossRefPubMed

25.

Currow, D. C., Plummer, J. L., Kutner, J. S., Samsa, G. P., & Abernethy, A. P. (2012). Analyzing PHASE III studies in hospice/palliative care: A solution that sits between intention-to-treat and per protocol analyses: The palliative-modified ITT analysis. Journal of Pain and Symptom Management, 44(4), 595–603. https://doi.org/10.1016/j.jpainsymman.2011.10.028CrossRefPubMed

Titel: Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503
verfasst von: Ayako Matsuda
Kazue Yamaoka
Hideo Kunitoh
Takashi Seto
Masahiro Tsuboi
Tatsuo Ohira
Riichiroh Maruyama
Hiroaki Okamoto
Kaoru Kubota
Publikationsdatum: 01.05.2023
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 9/2023
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-023-03424-y

Springer Professional

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 9/2023

Content validation of a daily patient-reported outcome measure for assessing symptoms in patients with Small Intestinal Bacterial Overgrowth

Trajectories of health-related quality of life and their predictors in adult COVID-19 survivors: A longitudinal analysis of the Biobanque Québécoise de la COVID-19 (BQC-19)

Patients’ perspectives on irritable bowel syndrome: a qualitative analysis based on social media in China

Parent-youth convergence (and divergence) in reports about pediatric quality of life

A process-based approach to health-related quality of life as a “way of living”

Health-state utilities in long-term advanced melanoma survivors comparable with the general population

Premium Partner